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ABSTRACT 
Calcium (Ca2+) is a physiological key factor, and the precise modulation of free cytosolic 
Ca2+ levels regulates multiple cellular functions. Store-operated Ca2+ entry (SOCE) is a major 
mechanism controlling Ca2+ homeostasis, and is mediated by the concerted activity of the 
Ca2+ sensor STIM1 and the Ca2+ channel ORAI1. Dominant gain-of-function mutations in 
STIM1 or ORAI1 cause tubular aggregate myopathy (TAM) or Stormorken syndrome, while 
recessive loss-of-function mutations are associated with immunodeficiency. Here we report 
the identification and functional characterization of novel ORAI1 mutations in TAM patients. 
We assess basal activity and SOCE of the mutant ORAI1 channels, and we demonstrate that 
the G98S and V107M mutations generate constitutively permeable ORAI channels, while 
T184M alters the channel permeability only in the presence of STIM1. These data indicate a 
mutation-dependent pathomechanism and a genotype/phenotype correlation, as the ORAI1 
mutations associated with the most severe symptoms induce the strongest functional cellular 
effect. Examination of the non-muscle features of our patients strongly suggest that TAM and 
Stormorken syndrome are spectra of the same disease. Overall, our results emphasize the 
importance of SOCE in skeletal muscle physiology, and provide new insights in the 
pathomechanisms involving aberrant Ca2+ homeostasis and leading to muscle dysfunction. 
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INTRODUCTION 
Skeletal muscle physiology directly depends on changes in free cytosolic calcium (Ca2+) 
levels, and small disturbances in Ca2+ homeostasis can severely impact on muscle 
contraction, differentiation, or gene transcription. A major mechanism controlling Ca2+ 
homeostasis is store-operated Ca2+ entry (SOCE), which is triggered by Ca2+ store depletion 
of the endoplasmic/sarcoplasmic reticulum (ER/SR), and results in extracellular Ca2+ influx 
through Ca2+ release-activated Ca2+ (CRAC) channels as ORAI1 (MIM# 610277). This 
highly Ca2+-selective plasma membrane channel is composed of tetramers or hexamers 
forming three concentric rings around the central pore (Hou, et al. 2012; Thompson and 
Shuttleworth 2013; Cai, et al. 2016). Each ORAI1 subunit is composed of 4 alpha-helical 
transmembrane domains (M1 to M4) linked by two external (I and III) and one internal (II) 
loop, with the N- and C-termini facing the cytosol. The M1 transmembrane domain 
constitutes the ~55 Å long channel pore with an acidic glutamate ring at position E106 
forming the selectivity filter and, together with negative residues in the first external loop, 
conferring high selectivity for Ca2+ ions (Vig, et al. 2006; Zhou, et al. 2010; McNally, et al. 
2012; Frischauf, et al. 2015). The central segment of the pore contains a rigid hydrophobic 
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section responsible for the low channel conductance, a gating hinge controlling pore opening, 
and a basal component potentially avoiding backward Ca2+ efflux from the cytoplasm 
(Zhang, et al. 2011).  
Channel opening is mediated through the interaction of the cytoplasmic N- and C-termini of 
the ORAI1 subunits with STIM1 (MIM# 605921), a transmembrane protein in the ER/SR 
able to sense luminal Ca2+ (Muik, et al. 2008; Navarro-Borelly, et al. 2008; Zheng, et al. 
2013). Ca2+ store depletion induces a conformational change resulting in oligomerization and 
cytosolic extension of the STIM1 molecules. The exposure of lipid-binding and channel 
activating domains (CAD) promotes the accumulation of the STIM1 oligomers at junctional 
ER/SR structures near the plasma membrane, where they trap and gate the ORAI channels 
(Luik, et al. 2006; Stathopulos, et al. 2006; Park, et al. 2009).  
We previously identified STIM1 gain-of-function mutations as genetic cause of autosomal 
dominant tubular aggregate myopathy (TAM, MIM# 160565) (Bohm, et al. 2013). TAM 
mostly involves elevated creatine kinase (CK) levels and slowly progressive muscle 
weakness predominantly affecting the proximal muscles of the lower limbs, but also myalgia, 
cramps, and asymptomatic CK elevation have been described (Bohm, et al. 2013; Bohm, et 
al. 2014; Hedberg, et al. 2014; Walter, et al. 2015). Muscle biopsies from patients with TAM 
typically show regular arrays of 70-200 nm long membrane tubules as the main 
histopathological hallmark (Chevessier, et al. 2005). Tubular aggregates can also arise as 
secondary features in various inherited and acquired muscle disorders, and accumulate in 
normal muscle with age (Boncompagni, et al. 2012). All TAM mutations affect highly 
conserved amino acids in the Ca2+-sensing EF hand domains of STIM1. The only cytosolic 
STIM1 mutation R304W has been associated with Stormorken syndrome (MIM# 185070), a 
multisystemic disorder involving tubular aggregate, elevated CK levels, miosis, 
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thrombocytopenia, ichthyosis, asplenia, dyslexia, and short stature (Misceo, et al. 2014; 
Morin, et al. 2014; Nesin, et al. 2014). Mutations in STIM1 causing either TAM or 
Stormorken syndrome were both shown to induce constitutive STIM1 oligomerization, 
CRAC channel activation and Ca2+ influx in the absence of store depletion (Bohm, et al. 
2013; Bohm, et al. 2014; Misceo, et al. 2014; Nesin, et al. 2014). Recently, three gain-of-
function mutations causing TAM or a Stormorken-like syndrome were also described in 
ORAI1 (Nesin, et al. 2014; Endo, et al. 2015). These mutations did not alter ORAI1 
localization at the plasma membrane, but resulted in increased SOCE and diminished Ca2+-
dependent channel inactivation (CDI). 
This study reports the identification of three ORAI1 gain-of-function mutations (two in the 
channel pore and one in M3) in patients with TAM with or without isolated characteristics of 
Stormorken syndrome. Based on clinical, histological, genetic, and functional data, we 
establish a genotype/phenotype correlation and conclude that TAM and Stormorken 
syndrome clinically overlap, and have to be considered as spectra of the same disease. We 
provide the functional evidence that mutations in the first transmembrane domain induce a 
STIM1-independent permeable Ca2+ channel resulting in a more severe phenotype, while the 
mutation in the third transmembrane domain requires activation through STIM1 to generate 
an excessive Ca2+ influx and causes a milder phenotype, suggesting that the ORAI1 mutations 
involve different pathological mechanisms.  
 
MATERIALS AND METHODS 
Patients 
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Sample collection was performed with informed consent from the patients according to the 
declaration of Helsinki and experimentation was performed following institutional IRB-
accepted protocols and the Comité de Protection des Personnes Est IV (DC-2012-1693). 
Patients were from Honduras (Family 1), the United Kingdom (Family 2), and Italy (Family 
3). 
Sequencing and segregation analysis 
Genomic DNA was prepared from peripheral blood by routine procedures and STIM1 
mutations were excluded by Sanger sequencing. Whole exome sequencing was carried out 
for patient 11200 from Family 1, and for patients II.1, II.3, and IV.1 from Family 2 using the 
SureSelect Human All Exon Kit v4 (Agilent, Santa Clara, USA) and the Illumina HiSeq 2000 
or 2500 systems (San Diego, USA). Sequence data were aligned to the GRCh37/hg19 
reference genome using the Burrows-Wheeler aligner software (http://bio-
bwa.sourceforge.net), and variant calling was performed with SAMtools (Li, et al. 2009) or 
the UnifiedGenotyper (https://www.broadinstitute.org/gatk). Following databases were used 
for SNP annotation and filtering: Exome Variant Server (http://evs.gs.washington.edu/EVS/), 
ExAC Browser (http://exac.broadinstitute.org/), dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/), 1000 genomes 
(http://www.1000genomes.org/), as well as the in-house exome databases in Illkirch and 
Manchester. Impacts of variations were predicted using Alamut v.2.5 
(http://www.interactive-biosoftware.com). 
For patient 5510 from Family 3, direct Sanger-sequenced for both coding exons of ORAI1 
and the adjacent splice-relevant regions was performed. Segregation analyses for Families 1 
and 2 were also performed by Sanger sequencing. The ORAI1 mutations were numbered 
according to GenBank NM_032790.3 and NP_116179.2. Nucleotide position reflects cDNA 
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numbering with +1 corresponding to the A of the ATG translation initiation codon. All 
identified mutations have been submitted to the LOVD database 
(http://www.lovd.nl/ORAI1). 
Histology and electron microscopy 
For histology, transverse sections (10 µm) of the muscle biopsies were stained with modified 
Gomori Trichrome, NADH tetrazolium reductase (NADH-TR) and Succinic dehydrogenase 
(SDH) and assessed for fiber morphology, fiber type distribution, and 
accumulations/infiltrations.  
For electron microscopy, muscle sections were fixed in 2.5% paraformaldehyde, 2.5% 
glutaraldehyde, and 50 mM CaCl2 in 0.1 M cacodylate buffer (pH 7.4). Samples were 
postfixed with 2% OsO4, 0.8% K3Fe(CN)6 in 0.1 M cacodylate buffer (pH 7.4) for 2 h at 4 °C 
and incubated with 5% uranyl acetate for 2 h at 4 °C. Muscles were dehydrated in a graded 
series of ethanol and embedded in epon resin. Thin sections were examined with an electron 
microscope (Philips CM120, FEI Company, Hillsboro, USA). 
Protein studies 
Immunofluorescence was performed with routine protocols using following antibodies: rabbit 
anti-Orai1 (Abcam, Paris, France), mouse anti-GOK/Stim1 (BD Biosciences, Franklin Lakes, 
USA), mouse Anti-Ryanodine receptor Clone 34C Product R-12 (Sigma-Aldrich, Saint 
Louis, USA), NCL-SERCA2 mouse monoclonal antibody, clone IID8 (Novocastra, 
Newcastle, UK). Sections were mounted with antifade reagent (Invitrogen, Carlsbad, USA) 
and viewed using a laser scanning confocal microscope (TCS SP2; Leica Microsystems, 
Wetzlar, Germany).  
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Constructs 
The human ORAI-eGPF and mCherry-STIM1 constructs were kind gifts from Liangyi Chen 
(Beijing University, China) and Richard S. Lewis (Stanford University, USA). The ORAI1 
point mutations (c.292G>A, c.319G>A, c.551C>T) were introduced by site-directed 
mutagenesis using the Pfu DNA polymerase (Stratagene, La Jolla, USA). The plasmid 
carrying an untagged STIM1 was purchased from OriGene (NM_003156; OriGene 
Technologies, Rockville, USA), and the control vector pEGFP-C1 from Clontech (Palo Alto, 
CA). 
Cells and transfections 
Stim1-/-/Stim2-/- mouse embryonic fibroblasts (MEF-DKO), generated by targeted gene 
disruption, were a kind gift from Masatsugu Oh-Hora (Tokyo Medical and Dental University, 
Japan), and HEK-293T cells were purchased from ATCC (CRL-11268; Manassas, USA). 
MEF-DKO and HEK-293T cells were respectively cultured in DMEM 15140-122 and 
31966-021 (Gibco Life Technologies, Carlsbad, USA) supplemented with 10% fetal bovine 
serum (10270-106, Gibco Life Technologies), 5 μg/ml streptomycin and 5 units/ml penicillin 
(15140-122, Gibco Life Technologies), and were maintained at 37 °C in 5 % CO2.  Cells 
were seeded on poly-L-lysine (P4832; Sigma-Aldrich) coated glass coverslips, and 
transfected at 50% confluency with Lipofectamine® 2000 (11668-019; Invitrogen). For co-
expression experiments, mCherry-STIM1 and ORAI1-eGFP constructs were transfected in a 
3:1 ratio by mass. For cells transfected with the ORAI1-eGFP G98S mutant and the 
respective controls, low Ca2+ containing medium (0.2 mM CaCl2) was used to prevent Ca2+ 
toxicity. All subsequent experiments were performed within 24h post transfection.  
TIRF microscopy 
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To assess the impact of the ORAI1 mutations on the channel distribution at the plasma 
membrane (PM), HEK-293T cells were co-transfected with wild type (WT) or mutated 
ORAI1-eGFP and an untagged STIM1 construct, and cultured overnight in low Ca2+ 
containing medium complemented with 5 µM lanthanum. The TIRF plane was determined 
according to the PM GFP fluorescence at resting state, and images were collected by a Nikon 
Eclipse Ti microscope (Tokyo, Japan) equipped with a Perfect Focus System, a 100x 1.49 Oil 
CFI Apochromat TIRF objective and a cooling EMCCD iXon camera (DU-897E-CS0-#BV-
500; Andor Technology Ltd, Belfast, Northern Ireland). Cells were excited with a 488 nm 50 
mW laser and light was collected through the TIRF Quad dichroic beamsplitter 
405/488/561/640 and the emission filter FITC 525/50 from Nikon. The experiment was 
performed at room temperature. Cells were treated with 1 µM Thapsigargin (Sigma-Aldrich) 
to follow the kinetics of ORAI1 clustering at the PM. Live images were acquired with the 
NIS-Elements AR software V4.30.02 (Nikon), and ORAI1 clusters were quantified and 
characterized with a granularity detection journal on Metamorph software 7.8.12.0 
(Molecular Devices, Sunnyvale, USA) after background subtraction. Regions containing 
clusters were identified at the end of each experiment and their increasing intensities were 
plotted over time. The results were normalized as follows: Fc(t=n) = (Fcr(t=n) - Frr(t=n)); F/F0(t=n) 
= (Ʃ Fc(t=n)/nb. clusters + Frr(t=0))/ Frr(t=0), where Fc(t=n) is the fluorescence intensity of a 
cluster at a given time, Fcr(t=n) the intensity measured in a region that will contain a cluster 
following store depletion, and Frr(t=n) the intensity of a reference region devoid of clusters 
throughout the experiment. The average fluorescence intensity of cumulated clusters at the 
cellular level (F(t=n)) was normalized to the fluorescence of the empty region at the beginning 
of the experiment (F0=Frr(t=0)). The percentage of the PM covered by clusters (density) was 
determined as the summed area of clusters divided by the total surface of the PM visible in 
the TIRF plane.  
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Ca2+ measurements 
To assess cytosolic Ca2+ levels, cells were loaded at room temperature with 4 µM of the Ca2+ 
sensor Fura-2 AM and 1 µM Pluronic acid F-127 (F-1201 and P-3000MP; Invitrogen) in 2 or 
0.2 mM CaCl2 recording solution. After 30 minutes in the dark, cells were washed and 
allowed for de-esterification for at least 15 min. Fura-2 ratiometric fluorescence emission was 
recorded with an Axio Observer microscope (Zeiss, Jena, Germany) equipped with a Lambda 
DG4 175 watts xenon arc lamp (Sutter Instrument Company, Novato, USA) and a rapidly 
changing filter wheel (Ludl Electronic Products, München, Germany). Excitation filters 
340AF15 and 380AF15 were purchased from Omega Optical (Brattleboro, USA). Exposure 
time was 500 ms every 3 seconds for each wavelength. Emission was collected through the 
dichroic/filter couple 415DCLP/510WB40 (Omega Optical), by a 12-bit CCD cooling 
camera (CoolSnap HQ, Ropper Scientific, Trenton, USA) with a 2x gain and a binning of 4. 
To measure store-operated Ca2+ entry, 1 µM Thapsigargin was used to passively deplete the 
Ca2+ stores. For Mn2+ quenching experiments, 500 µM Mn2+ were added while cells were 
excited at 360 nm (360BP10, Omega Optical). Recording solutions contained 140 mM NaCl, 
5 mM KCl, 1 mM MgCl2, 10 mM Hepes, 10 mM D-(+)-glucose and the indicated amounts of 
CaCl2. The Ca2+-free solution contained 1 mM EGTA instead of CaCl2. The pH was adjusted 
to 7.4 at 37 °C with NaOH. All experiments were achieved at 37 °C with pre-heated 
solutions. Ca2+ recordings were acquired and analyzed with the Metafluor 6.3 software 
(Universal Imaging, West Chester, USA) after background subtraction. For cells co-
expressing mCherry-STIM1 and ORAI1-eGFP constructs, only cells with a mCherry/eGFP 
fluorescence ratio above 1 were analyzed. 
Statistics 
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GraphPad Prism 6.05 was used for statistical evaluation of the data. Statistical significance 
was determined by the two-tailed unpaired Student's test with systematic Welch correction 
for variance. 
 
RESULTS 
Clinical reports 
The patients characterized in this study belong to three unrelated families with a broad range 
of symptoms and signs with different ages of onset and disease severity, but sharing 
prominent tubular aggregates on muscle biopsies as the main histopathological hallmark. 
Patient 11200 (Family 1) is a singleton, Family 2 has an ancestral history of a muscle 
phenotype segregating as a dominant disease over at least four generations, and Family 3 
displays a mother to son disease inheritance (clinical features summarized in Table 1).  
Patient 11200 from Family 1 is now 12 years old. Pregnancy, birth and neonatal history were 
uneventful, although motor milestones were slightly delayed. The patient achieved sitting at 
the age of 8 months, and independent walking at 24 months. Tip-toe-walking and frequent 
falls were noticed since age 2, and contractures of elbows and Achilles tendons were 
diagnosed in the following years. Clinical examination at the age of 10 revealed ichthyosis, 
stiffness, proximal muscle weakness and reduced tendon reflexes of the lower limbs. The 
patient was unable to jump, and had a waddling gait. He reported cramps and myalgia, both 
at rest and after exercise, headaches, and frequent episodes of bleeding from mouth, nose, and 
bowel. He had anemia but not thrombocytopenia, and blood calcium levels were repeatedly 
normal or only mildly reduced.  Eye examination showed miosis, heart and lung functions 
were normal, and cognitive assessment showed results within the normal range. CK levels 
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were repeatedly elevated, with values up to 2052 U/l. Motor nerve conduction velocities were 
normal and EMG showed chronic neurogenic abnormalities and mild myopathic changes in 
the proximal lower limbs. Muscle MRI revealed fibro-fatty replacements in the posterior and 
medial compartments of the thigh and of the posterior compartment of the calf (Supp. Figure 
S1). Abdominal ultrasound excluded asplenia/hyposplenia. The parents and the younger sister 
are healthy. 
For Family 2, five affected members underwent regular clinical examinations. They are now 
between 6 and 47 years old, and pregnancy, birth, and early childhood was normal for all. 
Slightly delayed motor milestones as well as slight dyslexia were reported for patients IV.1, 
and IV.2, and might have been overlooked for the older generations. All showed tip-toe 
walking associated to Achilles tendon contractures by the age of 8 years. Only the youngest 
patient, now 6 years old, does not show tip-toe walking. The proximal muscle of the lower 
limbs were predominantly affected, and involved weakness (II.1, III.1, III.2), stiffness (II.1, 
III.2), cramps (II.1, III.2), and myalgia (II.1, III.1, IV.1, IV.2). All had difficulties running 
and climbing stairs. Calf hypertrophy was noted for patients III.1 and IV.1. CK levels were 
elevated for all and ranged between 484 and 1538 U/I. Motor nerve conduction velocity, 
assessed for patient III.1 was normal, and EMG showed myopathic changes.  
Patient 5510 from Family 3 was diagnosed with asymptomatic hyperCKemia through routine 
blood tests at the age of 56. Medical examination at age 60 revealed mild general muscle 
weakness, and the patient reported myalgia of the lower limbs and cramps, but motor nerve 
conduction velocity and EMG did not reveal any abnormalities. The patient also presented 
with hypereosinophilia resulting from allergic diathesis, pectus excavatum, and arched palate. 
CK levels were repeatedly elevated and ranged between 400 and 600 U/I, and his mother was 
also reported to have asymptomatic hyperCKemia.  
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Histology and ultrastructural analyses reveal tubular aggregates  
Muscle biopsies from all patients described in this study displayed tubular aggregates 
appearing on Gomori trichrome and on NADH-TR staining (Figure 1). In agreement with 
previously described TAM cases, the aggregates are less detectable with SDH, suggesting a 
reticulum and not a mitochondrial origin (Chevessier, et al. 2005; Bohm, et al. 2013). 
Aggregates were observed in both fiber types in all analyzed biopsies. Additional 
observations comprise fiber size variability and internalized nuclei.  
Ultrastructural analyses demonstrated that the tubular aggregates are of variable size and 
consist of single or double-walled membranes of different diameter (Figure 1). Overall, the 
histological and ultrastructural features of the biopsies were strikingly similar and strongly 
suggestive of tubular aggregate myopathy. 
Exome sequencing identifies mutations in ORAII 
Sanger sequencing of the known TAM gene STIM1 did not reveal any putative pathogenic 
variant in the families described here. We performed exome sequencing for Families 1 and 2, 
and identified heterozygous missense mutations in ORAI1. Patient 11200 from Family 1 
carries the ORAI1 c.292G>A (p.Gly98Ser) de novo mutation in exon 1, and the affected 
members of Family 2 harbor the ORAI1 c.319G>A (p.Val107Met) mutation in exon 2 (Figure 
2A). Another missense mutation (c.551C>T; p.Thr184Met) in exon 2 was found by direct 
ORAI1 Sanger sequencing of patient 5510 from Family 3. None of the three mutations was 
found in the available healthy family members and none was listed in the public or internal 
SNP databases. However, the p.Gly98Ser mutation was previously described in an unrelated 
Japanese family with TAM involving diffuse muscle weakness, joint contractures, a rigid 
spine and hypocalcaemia (Endo, et al. 2015). 
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All three missense mutations affect highly conserved amino acids in ORAI1 (Figure 2B) The 
mutations p.Gly98Ser and p.Val107Met affect amino acids in M1, and p.Thr184Met affects 
an amino acid in M3 (Figure 2C). M1 forms the ion conduction pathway, while M2 and M3 
encircle the pore and are surrounded by the M4 outer ring (Hou, et al. 2012; Frischauf, et al. 
2015). The residue G98 is located in the rigid section of the channel responsible for ion 
conduction, and the residue V107 neighbors E106, involved in Ca2+ selectivity. 
Tubular aggregates contain STIM1 
To characterize the structure and composition of the tubular aggregates associated with 
ORAI1 mutations, we performed immunolocalization experiments on muscle biopsies from 
patient 11200 (Family 1) and II.1 (Family 2) (Figure 1). We previously showed that tubular 
aggregates in TAM patients with STIM1 mutations contain various SR proteins as STIM1, the 
Ca2+ channel RYR1 (MIM# 180901), the RYR1-effector triadin (MIM# 603283), or the Ca2+ 
pump SERCA (MIM# 108730), and that RYR1 and STIM1 are exclusively found in the 
aggregate periphery (Bohm, et al. 2013). In agreement with our previous observations, the 
aggregates in the TAM patients with ORAI1 mutations also contain SERCA, and RYR1 is 
mainly found in the periphery of the aggregates (Figure 1). The aggregates display strong 
STIM1 signals, thereby linking STIM1 and ORAI1-related TAM. Of note, STIM1 signals are 
not restricted to the aggregate periphery; this is in contrast to the immunolocalization 
experiments in STIM1 patients, and might reflect different ways of tubular aggregate 
formation in patients with STIM1 or ORAI1 mutation. Aggregated ORAI1 is barely or not 
detectable on the biopsies of the analyzed patients, supporting the idea that tubular aggregates 
essentially consist of sarcoplasmic reticulum membrane and proteins. 
ORAI1 mutants traffic normally to plasma membrane clusters  
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In order to assess the impact of the three ORAI1 mutations on channel localization and 
trafficking, we generated wild type (WT) and ORAI1-eGFP G98S, V107M, and T184M 
constructs, exogenously co-expressed them with human STIM1 in HEK-293T cells, and 
imaged the formation of ORAI1 clusters at the PM by total internal reflection fluorescence 
(TIRF) microscopy. WT and mutant ORAI1 were homogenously distributed in the TIRF 
plane in resting cells, and accumulated in clusters following depletion of ER Ca2+ stores with 
the SERCA inhibitor Thapsigargin (Tg) (Figure 3A). The intensity of the clusters and the 
extent of cell membrane covered by clusters was comparable in cells expressing WT or 
mutant ORAI1 at resting or activated state (Figure 3B and 3C). We therefore conclude that 
the mutations do not significantly alter the ORAI1 localization at the plasma membrane, nor 
its clustering upon SOCE activation. 
ORAI1 mutations produce constitutively active channels   
To evaluate the impact of the ORAI1 mutations on the basal channel activity, we measured 
the cytosolic Ca2+ levels ([Ca2+]cyt) in HEK-293T cells transfected with the ORAI1-eGFP 
constructs, and loaded with the ratiometric Ca2+ sensor Fura-2, AM. Cells were sequentially 
exposed to Ca2+-rich and Ca2+-poor media to assess the extent of Ca2+ entry across the 
channel in cells with replete stores (Figures 4A-C). Mean basal Fura-2 ratio values were 
elevated in cells expressing ORAI1 V107M (0.52, SD ± 0.14) or T184M (0.48, SD ± 0.10) 
compared to cells expressing WT ORAI1 (0.39, SD ± 0.08), and decreased significantly upon 
Ca2+ removal. HEK-293T cells expressing the ORAI1 G98S construct displayed extremely 
high [Ca2+]cyt in Ca2+-rich conditions and were cultured in 0.2 mM CaCl2 to minimize 
cytotoxicity. Under these conditions, mean basal Fura-2 ratio was significantly elevated 
(0.68, SD ± 0.19, compared to WT 0.35, SD ± 0.03), decreased upon Ca2+ removal, and 
markedly increased upon addition of 2 mM Ca2+ (1.28, SD ± 0.20, compared to WT 0.36, SD 
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± 0.04, Figures 4B and 4C). These results suggest that the mutated ORAI1 channels are Ca2+ 
permeable even in the absence of store depletion, with a more pronounced degree of 
permeability for G98S compared to V107M or T184M ORAI1. 
G98S and V107M alter ORAI1 activity independently of STIM1 
In order to assess the STIM-dependence of the constitutive activation of mutant ORAI1 
channels, we next transfected mouse embryonic fibroblasts bearing a targeted disruption in 
the Stim1 and Stim2 genes (MEF-DKO). Since steady-state [Ca2+]cyt reflects the combined 
activity of Ca2+ pumps, channels and exchangers, we used the Mn2+ quench assay (Figures 
4D-F). Mn2+ permeates through Ca2+ channels and quenches the Fura-2 fluorescence, thereby 
allowing the individual quantification of the influx component. In these experiments, we 
observed a massive Mn2+ influx in MEF-DKO cells expressing ORAI1-eGFP V107M or 
G98S, while only a small Mn2+ influx was detectable in cells expressing ORAI1-eGFP 
T184M or WT, with no significant difference among these two conditions. Similar results 
were obtained by measuring the amplitude of the Ca2+ elevation evoked by the readmission of 
2 mM Ca2+ to MEF-DKO cells treated with Tg (Supp. Figure S2), where Fura-2 ratio 
increase was observed only in cells expressing G98S or V107M ORAI1. In conclusion, G98S 
and V107, but not T184M ORAI1 channels appear constitutively active in the absence of 
STIM proteins. Accordingly, Mn2+ quench experiments in HEK-293T cells endogenously 
expressing STIM1 and STIM2 demonstrated that cells transfected with any of the mutant 
channels including ORAI1-T184M displayed significant cation entry (Supp. Figure S3). 
The ORAI1 mutants mediate excessive Ca2+ entry when gated by STIM1 
To test whether the ORAI1 mutations also impact on the STIM1-gated maximal channel 
activity, we co-transfected HEK-293T cells with mCherry-STIM1 and WT or mutated 
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ORAI1-eGFP constructs. We induced passive reticular Ca2+ depletion through Tg treatment 
in Ca2+-free medium, and measured SOCE upon readmission of 0.5 mM Ca2+ to the medium. 
Cells expressing any of the ORAI1 mutants displayed significantly increased SOCE with 2-3 
fold steeper slope of Fura-2 ratio increase compared to cells expressing WT ORAI1 (Figures 
5A and 5B). Analysis of the response kinetics 60 s after Ca2+ admission demonstrated a 30 % 
Fura-2 ratio decrease for cells transfected with WT or T184M ORAI1, while the ratio 
remained at near maximal levels in cells expressing G98S or V107M ORAI1 (Figure 5C).  
To specifically assign ORAI1 channel activation to STIM1, we repeated the co-expression 
experiments in MEF-DKO cells (Figures 5D-F). Following Tg treatment and readmission of 
Ca2+, cells co-expressing STIM1 and V107M or T184M ORAI1 mutants displayed a strongly 
increased SOCE slope compared to cells co-expressing STIM1 and WT ORAI1. Expression 
of a control vector did not affect the Ca2+ response of the recipient cells, and expression of 
STIM1 alone fully restored SOCE in the MEF-DKO cells (Supp. Figure S2). Unexpectedly, 
MEF-DKO expressing STIM1 and WT or G98S ORAI1 and cultured in low Ca2+ exhibited a 
high SOCE slope (Figures 5D-E), potentially reflecting a specific adaptation of these cells to 
Ca2+ deprivation, and resulting in a more efficient activation of the SOCE pathway. However, 
and in agreement with the results obtained in transfected HEK-293T cells, the Fura-2 ratio 
remained elevated 60 s post Ca2+ readmission in cells expressing the G98S and V107M 
mutants while the ratio decreased in cells expressing T184M ORAI1 (Figure 5F).  
Overall and in accordance with the Mn2+ quenching data, these results strongly indicate a 
mutation-dependent pathomechanism. All three ORAI1 mutations G98S, V107M, and 
T184M involve maximal SOCE in presence of active STIM1, but only G98S and V107M 
generate a constant Ca2+ influx independently of STIM1 activation.  
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DISCUSSION 
Here we report three ORAI1 mutations causing tubular aggregate myopathy, and we support 
our findings by clinical, histological, genetic and functional data. Our patients presented with 
different age of onset, disease severity, and additional non-muscular features, suggesting that 
TAM and Stormorken syndrome are spectra of the same disease. We functionally 
demonstrate for the first time that the mutations in different ORAI1 transmembrane domains 
appear to involve different pathomechanisms, and thereby uncover a genotype-phenotype 
correlation. 
Tubular aggregates in ORAI1 patients contain STIM1  
As both STIM1 and ORAI1 mutations lead to TAM, we compared the structure and 
composition of the tubular aggregates in our ORAI1 patients with the published STIM1 
patients (Bohm, et al. 2013). The tubular aggregates in STIM1 patients were shown to contain 
diverse sarcoplasmic reticulum proteins as RYR1, triadin, SERCA, and STIM1, and STIM1 
was mainly found in the periphery of the aggregates (Bohm, et al. 2013). 
Immunohistofluorescence on muscle sections from ORAI1 patients also demonstrated the 
presence of STIM1 and other sarcoplasmic reticulum proteins in the aggregates. This 
observation provides a link between STIM1 and ORAI1-related TAM at the histopathological 
level, and suggests that secondary STIM1 aggregation plays a role in the pathogenesis of 
ORAI1 mutations. Of note, the STIM1 signals were detectable in the periphery as well as in 
the center of the aggregates, potentially reflecting a difference in tubular aggregate formation 
in patients with STIM1 and ORAI1 mutation. Even if mutated, the plasma membrane Ca2+ 
channel ORAI1 is barely or not detectable in the aggregates, confirming that the tubular 
aggregates are primarily of sarcoplasmic reticulum origin. Considering the increased Ca2+ 
entry resulting from STIM1 or ORAI1 mutations, we might speculate that the excessive 
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cellular Ca2+ is in large parts stored in the reticulum, provoking reticular overload and 
dilatation, and resulting in cisternal pinching off to form the primary stage of the tubular 
aggregates. This is line with the observation that tubular aggregates contain large amounts of 
Ca2+ (Salviati, et al. 1985; Chevessier, et al. 2005). 
ORAI1 mutations involve different pathomechanisms 
To mechanistically investigate the impact of the ORAI1 G98S, V107M, and T184M 
mutations, we analyzed the channel activity in presence or absence of STIM1. Expression of 
any of the mutant ORAI1-eGFP constructs in HEK-293T cells resulted in elevated basal Ca2+ 
levels, but in mouse fibroblasts devoid of STIM (Stim1-/-/Stim2-/-), only G98S and V107M 
induced significant cation influx in the Mn2+ quench assay. This demonstrates that both G98S 
and V107M ORAI1 channels are constantly permeable for Ca2+, while the overactivity of the 
T184M ORAI1 channel is conditioned by the presence of STIM. Accordingly, and 
considering that the constant fluctuation of Ca2+ levels within cellular compartments results 
in a varying sub-pool of activated STIM1/STIM2, and that STIM2 with is lower Ca2+ affinity 
and higher lipid-binding avidity has been shown to be pre-recruited to the cortical ER at basal 
ER Ca2+ concentrations (Parvez, et al. 2008), the endogenous STIM proteins in HEK-293T 
cells might be sufficient to partially activate the T184M ORAI1 channel. It is possible that 
the T184M mutation increases the binding sensitivity of the channel to STIM1 and STIM2 or 
to the transient receptor potential canonical (TRPC) channels to form a ternary complex with 
STIM1 at the plasma membrane (Lu, et al. 2010), which might explain the higher basal Ca2+ 
level in cells expressing the T184M mutant even in the absence of store depletion. The 
extensive characterization of the T184M mutation might reveal a residue or domain 
regulating STIM-mediated channel gating. Excessive Ca2+ entry was also reported for other 
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ORAI1 mutations (Nesin, et al. 2014; Endo, et al. 2015), but the STIM-dependence of the 
channel activation was not investigated in these studies. 
Further evidence for a different pathomechanism of the ORAI1 mutations comes from the co-
expression experiments. HEK-293T or MEF-DKO cells co-expressing mCherry-STIM1 and 
any of the ORAI1-eGFP mutants induced excessive Ca2+ influx following SOCE activation, 
but only G98S and V107M generated a continuous and long lasting Ca2+ influx. In contrast, 
Ca2+ influx significantly decreased over time in HEK-293T or MEF-DKO cells co-expressing 
STIM1 and T184M ORAI1. This discrepancy potentially reflects a difference in Ca2+-
dependent inactivation (CDI) of the mutant channels and/or their dissociation kinetics from 
STIM1. Alternatively, the higher basal Ca2+ levels in cells expressing ORAI1 G98S or 
V107M might increase the threshold triggering CDI or Ca2+ extrusion. It is also possible that 
the G98S and V107M mutations directly or indirectly impact on the Ca2+ extrusion systems.  
In summary, our results suggest a mutation-specific pathomechanism. G98S and V107M 
induce constitutive channel opening independently of STIM, while T184M overactivation is 
conditioned by the presence of STIM. In accordance, the amino acid G98 resides in the 
hydrophobic gating hinge, and V107 locates near the Ca2+ selectivity filter of the M1 
transmembrane domain (Zhou, et al. 2010; Hou, et al. 2012). Disturbance of these key 
functions is expected to impact on ion flow, which is confirmed by our functional data 
demonstrating constitutive Ca2+ permeability independently of STIM. This conclusion is also 
sustained by similar findings based on the functional characterization of artificial M1 
mutations (Zhang, et al. 2011). Conversely, T184 is not located in the channel pore, and the 
STIM-dependent overactivation of the mutant channel strongly suggests that transmembrane 
domain M3 is directly or indirectly implicated in STIM-mediated ORAI1 gating. 
ORAI1 mutations in M1 induce a more severe phenotype 
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Considering the clinical presentation of our and all previously published patients with 
activating ORAI1 mutations (Nesin, et al. 2014; Endo, et al. 2015), the most severe muscle 
phenotypes result from mutations in M1, a moderate muscle phenotype from a mutation in 
M2, and milder muscle phenotypes from mutations in M3 and M4. This correlates well with 
our functional data, demonstrating a stronger impact of M1 mutations on channel function.  
Our patients were diagnosed with tubular aggregate myopathy based on biochemical blood 
tests and histological findings. All displayed repeatedly elevated serum CK levels in 
combination with prominent tubular aggregates as the major structural aberration on muscle 
biopsies. The clinical presentation was however variable, ranging from severe early-onset 
muscle weakness and contractures (patient 11200 from Family 1) to mild late-onset muscle 
weakness (patient 5510 from Family 3). A similar interfamilial variability was recently 
described for other families with ORAI1 mutations. G98S was described in two Japanese 
family presenting childhood-onset TAM, joint contractures, hypocalcaemia, rigid spine, and 
elevated CK levels (Endo, et al. 2015). We identified the same mutation in our unrelated 
Family 1, and the clinical manifestations were comparable. The same study reported a third 
Japanese family harboring the ORAI1 L138F mutation, and presenting with weaker clinical 
features involving adolescence-onset TAM, minor joint contractures, and slightly elevated 
CK levels. In addition, a family carrying the ORAI1 P245L mutation was described with late-
onset TAM and increased CK levels (Nesin, et al. 2014).  
Taking into account the clinical manifestation of all TAM patients with ORAI1 mutation, our 
functional data, and the published ORAI1 protein structure, we conclude that mutations 
affecting the pore lead to constitutive channel permeability, and result in early-onset muscle 
weakness often associated with contractures. In contrast, mutations affecting the concentric 
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channel rings involve a STIM-dependent overactivity of ORAI1, and result in less severe 
symptoms with minor muscle weakness.  
ORAI1 patients present discrete signs of Stormorken syndrome  
Tubular aggregate myopathy in combination with miosis, thrombocytopenia, asplenia, 
ichthyosis, dyslexia/intellectual disability, and short stature defines Stormorken syndrome. 
Both TAM and Stormorken syndrome are caused by gain-of-function mutations in STIM1 
and ORAI1 (Bohm, et al. 2013; Misceo, et al. 2014; Morin, et al. 2014; Nesin, et al. 2014; 
Endo, et al. 2015). To explore the possibilities that TAM and Stormorken syndrome are either 
different nosological entities or spectra of the same disease, we examined our patients for 
non-muscle phenotypes and reviewed the published ORAI1 cases. We noticed miosis (patient 
11200, Family 1, and (Nesin, et al. 2014)), frequent episodes of bleeding (patient 11200, 
Family 1), ichthyosis, (patient 11200, Family 1), and dyslexia/intellectual disability (patients 
IV.1, and IV.2, Family 2, Family A (Endo, et al. 2015)). These data show that signs of 
Stormorken syndrome are found in many patients with activating ORAI1 mutations, and we 
conclude that TAM and Stormorken syndrome are spectra of the same disease. This is of high 
importance for genetic diagnosis and counseling, as ORAI1 mutations should be considered 
in patients with elevated CK levels and prominent tubular aggregates on muscle biopsies, 
especially if they present signs of Stormorken syndrome. 
Overactive SOCE versus underactive SOCE in Mendelian disorders 
STIM1 and ORAI1 act within the same SOCE pathway regulating Ca2+ homeostasis in 
various tissues. The identification of gain-of-function mutations in STIM1 and ORAI1 
represents a strong proof for the implication of aberrant SOCE in the development of 
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TAM/Stormorken syndrome. This is sustained by our functional and immunolocalization 
studies demonstrating a pathomechanistic link between both proteins. 
While heterozygous gain-of-function mutations in STIM1 or ORAI1 generate excessive Ca2+ 
influx and result in the development of TAM/Stormorken syndrome (Bohm, et al. 2013; 
Bohm, et al. 2014; Hedberg, et al. 2014; Misceo, et al. 2014; Morin, et al. 2014; Nesin, et al. 
2014; Endo, et al. 2015; Markello, et al. 2015), homozygous loss-of-function mutations in 
either of the genes suppress Ca2+ influx and are associated with severe immunodeficiency 
(Feske, et al. 2006; McCarl, et al. 2009; Picard, et al. 2009; Byun, et al. 2010; Fuchs, et al. 
2012; Lacruz and Feske 2015) (MIM# 612782, # 612783). We conclude that strict regulation 
of Ca2+ homeostasis ensures normal physiology of muscle, leucocytes, platelets, skin, and 
other cells and tissues, and that overactive SOCE causes tubular aggregate 
myopathy/Stormorken syndrome, while underactive SOCE causes immunodeficiency.   
Conclusions 
Our work indicates for the first time a mutation-specific pathomechanism for ORAI1 gain-of-
function mutations, thereby uncovers a clear genotype-phenotype correlation, and improves 
the understanding of the pathology of TAM/Stormorken syndrome and store-operated Ca2+ 
entry, altered in rare and common diseases. 
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FIGURE LEGENDS  
Figure 1 - Histological, ultrastructural, and immunohistochemical characterization of 
the biopsies 
 (A) Muscle biopsies from patients from all three families display tubular aggregates 
appearing in red on Gomori trichrome and in dark blue on NADH-TR staining in both fiber 
types. The aggregates are barely detectable with SDH. Minor fiber size variability and 
internalized nuclei are also noted. Ultrastructural analyses demonstrate that the tubular 
aggregates are of variable size and consist of single or double-walled membranes of different 
diameter. EM pictures were not available for Family 2. (B) Immunolocalization studies on 
biopsies from Family 1 and Family 2 show that the tubular aggregates contain STIM1, 
RYR1, SERCA, whereas ORAI1 is barely or not trapped. Note that STIM1 signals are found 
in the periphery and in the center of the aggregates, while RYR1 is mainly found in the 
periphery (arrows). * indicate identical fibers of serial sections. 
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Figure 2 - Identification of ORAI1 mutations 
(A) Heterozygous ORAI1 missense mutations were identified in all three families, and 
segregated with the disease. (B) The mutations affect highly conserved amino acids in 
ORAI1. (C) Schematic representation of ORAI1. Mutations found in our patients are depicted 
in blue, published mutations appear in red. G98S and V107M affect amino acids in 
transmembrane domain 1 (M1), and T84M affects an amino acid in M3. Residue G98 is 
located in the rigid section of the channel, and V107 neighbors the Ca2+ selectivity filter 
E106.  
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Figure 3 - Effect of ORAI1 mutations on channel localization and clustering at the PM 
(A) TIRF images of HEK-293T co-expressing STIM1 and wild-type (WT) or mutated 
(V107M, T184M, G98S) ORAI1-eGFP taken before and 10 min after addition of 1 µM 
Thapsigargin (Tg). Insets show cluster morphology at higher magnification. (B) Changes in 
intensity of eGFP clusters and in cluster density (% PM covered by clusters) in the TIRF 
plane following Tg addition in cells co-expressing STIM1 and WT or mutated ORAI1-eGFP. 
(C) Statistical evaluation of eGFP cluster intensity and density before and after Tg treatment. 
Data are mean ± SEM of 33, 24, 25, and 14 cells for WT, V107M, T184M and G98S, 
respectively. No statistically significant differences were observed between WT and mutated 
channels in resting and store-depleted conditions. 
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Figure 4 - Effect of ORAI1 mutations on basal Ca2+ level 
(A) Representative Fura-2 recordings of HEK-293T cells expressing wild-type (WT) or 
mutated (V107M, T184M) ORAI1-eGFP during Ca2+ removal (2 mM Ca2+ replaced by 1 
mM EGTA). (B) Recordings of cells expressing WT or G98S ORAI1-eGFP during Ca2+ 
removal and readmission. Cells were cultured in a Ca2+-poor medium (0.2 mM) to mitigate 
the toxicity associated with the G98S mutation. (C) Statistical evaluation of the responses 
illustrated in (A) and (B), measured between the time points indicated with # (n = 79, 39, 49 
for WT, V107M, T184M respectively, and n = 38, 20 for WT and G98S cultured in low 
Ca2+). (D), (E) Representative Mn2+ quench recordings of MEF-DKO cells (Stim1-/-/Stim2-/-) 
expressing WT or mutated ORAI1-eGFP. Fura-2 fluorescence was recorded at 360 nm in the 
presence of 2 mM Ca2+. Traces are offset to facilitate comparison. (F) Statistical evaluation of 
Mn2+ quench rates in (D) and (E), measured between the time points indicated with # (n = 17, 
20, 21 and 23, 32 for WT, V107M, T184M, and WT, G98S cultured in low Ca2+, 
respectively). Data are mean ± SEM, statistically significant differences versus respective 
WT conditions are indicated by **** p < 0.0001. 
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Figure 5 - Effect of ORAI1 mutations on maximal SOCE 
(A), (D) Fura-2 responses evoked by the readmission of 0.5 mM Ca2+ (HEK-293T) or 2 mM 
Ca2+ (MEF-DKO) to cells co-expressing mCherry-STIM1 and ORAI1-eGFP (WT, V107M, 
T184M or G98S) treated with Tg. (B), (E) Statistical evaluation of the influx rate evoked by 
Ca2+ readmission in (A) and (D), measured as the Fura-2 increase slope between the time 
points indicated with #. (C), (F) Statistical evaluation of the Ca2+ level 60 seconds after the 
peak of the response in (A) and (D), illustrated by the dotted line, and expressed as 
percentage of the peak. Data are mean ± SEM of 24-51 cells for (B), (C) and of 17-29 cells 
for (E), (F). Statistically significant differences versus respective WT conditions are indicated 
by ** p < 0.01, *** p< 0.001, and **** p < 0.0001.  
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Table 1. Genetic, clinical and histological features in patients with ORAI1 mutations 
 Family 1 Family 2 Family 3 
Individual 11200 I.1 II.1 II.2 III.1 III.2 IV.1 IV.2 5510 
Gender M F F M F F M M M 
Mutation 
c.292G>A 
p.Gly98Ser 
c.319G>A 
p.Val107Met 
c.319G>A 
p.Val107Met 
c.319G>A 
p.Val107Met 
c.319G>A 
p.Val107Met 
c.319G>A 
p.Val107Met 
c.319G>A 
p.Val107Met 
c.319G>A 
p.Val107Met 
c.551C>T 
p.Thr184Met 
Onset childhood unknown childhood unknown childhood childhood childhood childhood adulthood 
Age at last examination 10 no examination 47 no 
examination 25 31 8 6 60 
Muscle symptoms 
proximal and distal 
weakness of lower 
limbs, myalgia, 
cramps, stiffness 
NA stiffness, 
cramps NA 
proximal 
weakness of 
lower limbs, 
exercise-induced 
myalgia 
weakness of 
arms, cramps 
myalgia, 
stiffness myalgia 
mild general 
weakness, myalgia 
in lower limbs, 
cramps 
Walking tip-toe walking, 
waddling gait NA 
tip-toe walking, 
difficulty 
climbing stairs 
NA 
tip-toe walking, 
difficulty 
climbing stairs 
tip-toe 
walking 
tip-toe 
walking normal normal 
Contractures elbows, Achilles 
tendons NA Achilles tendons NA Achilles tendons NA 
Achilles 
tendons 
Achilles 
tendons no 
CK level (U/I) 2052 NA 791 NA 1383 597 1538 484 600 
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normal range 60-180 
Histology 
TAs in type I/II 
fibers, fiber size 
variability, 
internalized nuclei 
NA 
TAs in type I/II 
fibers, fiber size 
variability, 
internalized 
nuclei 
NA NA NA NA NA 
TAs in type I/II 
fibers, fiber size 
variability, 
internalized nuclei 
Signs of Stormorken 
syndrome 
ichtyosis, miosis, 
bleeding episodes NA no NA no no dyslexia dyslexia no 
Other features occasional mild hypocalcemia 
COPD, 
cerebrovascular 
disease 
no NA calf hypertrophy no 
calf 
hypertrophy, 
seizures 
calf 
hypertrophy, 
scapular 
winging 
hypereosinophilia, 
pectus excavatum, 
arched palate 
NA = not assessed 
 
 
